Garrix Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.40 M
- Revenue Growth 199.62%
- Profit Growth 474.63%
- Ebitda 219.01%
- Net Worth 50.56%
- Total Assets 101.10%
About Garrix Pharma
Garrix Pharma Private Limited (GPPL) is a Private Limited Indian Non-Government Company incorporated in India on 28 July 2020 (Four years and six months 30 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.40 M.
Sudhakar Mishra and Gudia Mishra serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24290DL2020PTC366987
- Company No.
366987
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Jul 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Garrix Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sudhakar Mishra  | Director | 28-Jul-2020 | Current |
| Gudia Mishra | Director | 28-Jul-2020 | Current |
Financial Performance of Garrix Pharma.
Garrix Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 199.62% increase. The company also saw a substantial improvement in profitability, with a 474.63% increase in profit. The company's net worth Soared by an impressive increase of 50.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Garrix Pharma?
Unlock access to Garrix Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹0.40 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.04 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Feb 2023 | Others | ₹0.40 M | Open |
How Many Employees Work at Garrix Pharma?
Garrix Pharma has a workforce of 0 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Garrix Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Garrix Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.